Two BIOCAD products, Acellbia (INN: rituximab) and Herticad (INN: trastuzumab), received the first European registration certificate in Bosnia and Herzegovina.
Australian CRO Avance Clinical said that Australia’s fast regulatory approval environment, key opinion leader expertise and high-quality clinical research sites,
Global guidance for pharmacists in community, hospital and clinical biology on coronavirus/COVID-19 has been updated by the International Pharmaceutical Federation